Stanford researchers show blood immune cells flood the aging brain

Stanford researchers have shown that during aging, large numbers of immune cells from the bloodstream cross into the human brain and take on roles as microglia, the brain's specialized immune cells. The finding, published July 30 in Nature, reframes a half-century of neuroscience built on the assumption that the brain's immune system is largely separate from the rest of the body.

The work reads the accumulated DNA scars in individual cells and follows them like barcodes. Each time a blood stem cell divides, it picks up small, random mutations; those mutations propagate to its descendants, giving researchers a way to tell which microglia in postmortem brain tissue arose from the brain's own progenitor cells and which arrived from the bone marrow. The Stanford team applied that method to genetic data from thousands of people followed for decades, and the bone-marrow-derived share of microglia grew steadily with age, reaching substantial levels in older donors.

That growth contradicts the textbook model. The blood-brain barrier, a tightly packed layer of cells lining the brain's blood vessels, is supposed to keep most circulating cells and molecules out. Microglia were thought to arise almost entirely during early development from the brain's own progenitor cells, then patrol the tissue for the rest of a person's life. Anything that crossed in from outside was treated as damage, not design.

"We usually think of the brain as a closed system," said first author Julia Belk, a postdoctoral scholar in pathology at Stanford Medicine, in the institutional release. "This work shows that during aging, the brain is recruiting help from the outside."

Senior author Siddhartha Jaiswal, an associate professor of pathology at Stanford Medicine and a member of the Institute for Stem Cell Biology and Regenerative Medicine, said the result is the first direct demonstration in human tissue of a process that had been hinted at in mice and inferred from indirect evidence. The implication is that the blood-brain barrier is more porous during aging than the textbook account allowed, a porosity that may help explain why brain inflammation tends to rise with age and why disorders from Alzheimer's to Parkinson's involve immune components that have been hard to pin on brain-resident cells alone.

The paper does not claim that peripheral cells are the cause of any specific disease. It argues that any account of brain aging that treats the brain as immunologically isolated is now missing a major player. The research was supported in part by the Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute, which funds work on how the brain ages and how to slow that decline.

NIH Research Matters, a federal summary of the work, frames the result as a possible route to one day use peripheral immune cells as delivery vehicles for brain therapies, an approach that would require engineering cells outside the body, then letting the same age-related porosity carry them in. That treatment idea is forward-looking. The paper itself documents a mechanism, not a therapy, and the authors describe the therapeutic angle as a possibility rather than a near-term plan.

Independent coverage by trade outlets has restated the same mechanism story, and the federal and trade summaries align with the Nature paper's central claim: that the brain's immune system is partly reseeded from the body across a lifespan. For brain-aging research, the immediate effect is a change in baseline. Experiments that assume microglia are a sealed, brain-born population will need to account for a significant bone-marrow contribution in older subjects. The longer-term question is whether the same porosity can be steered toward repair rather than inflammation.